Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody-Reference-Cited by-同舟云学术

Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody

Published:2015-10-21 Issue:3 Volume:37 Page:4143-4157
ISSN:1010-4283
Container-title:Tumor Biology
language:en
Short-container-title:Tumor Biol.

Author:

Ciszak Lidia,Frydecka Irena,Wolowiec Dariusz,Szteblich Aleksandra,Kosmaczewska Agata

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13277-015-4217-1.pdf

Reference42 articles.

1. Hallek M, Pflug N. Chronic lymphocytic leukemia. Ann Oncol. 2010;21 Suppl 7:vii154–64. doi: 10.1093/annonc/mdq373 .

2. Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90(5):446–60. doi: 10.1002/ajh.23979 .

3. Herishanu Y, Polliack A. Chronic lymphocytic leukemia: a review of some new aspects of the biology, factors influencing prognosis and therapeutic options. Transfus Apher Sci. 2005;32(1):85–97. doi: 10.1016/j.transci.2004.10.012 .

4. Abbott BL. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist. 2006;11(1):21–30. doi: 10.1634/theoncologist.11-1-21 .

5. Caligaris-Cappio F, Bertilaccio MT, Scielzo C. How the microenvironment wires the natural history of chronic lymphocytic leukemia. Semin Cancer Biol. 2014;24:43–8. doi: 10.1016/j.semcancer.2013.06.010 .

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cross‐talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: An update review;European Journal of Haematology;2024-05-02

2. Current Approaches of Immune Checkpoint Therapy in Chronic Lymphocytic Leukemia;Current Treatment Options in Oncology;2023-08-10

3. Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors;International Journal of Molecular Sciences;2023-03-17

4. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy;Frontiers in Immunology;2023-01-27

5. The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies;Expert Opinion on Therapeutic Targets;2022-12-02